Abstract 2997
Background
UPTR remains controversial in the initial management of unresectable asymptomatic mCRC patients (pts), whereas right sidedness is a bad prognostic factor.
Methods
Retrospective pooled analysis of KRAS WT mCRC pts treated with 1st line EGFR inhibitors (EGFRI) + chemotherapy (CT) from two phase II randomised trials (MACRO-2 & PLANET). We analysed UPTR effect on overall survival (OS) and progression free survival (PFS) by tumour sidedness (right/left) and stage (I-III/IV) at diagnosis. All stage I-III pts underwent UPTR at diagnosis as standard procedure.
Results
260 pts were included in the analysis (Table). In pts with stage IV at diagnosis, UPTR was associated with a better OS, although differences were only significant in right sided tumours (mOS (m): 20.9 vs 10.6; HR non-UPTR vs UPTR 2.1 (1.0, 4.3); P = 0.038). Conversely, left sided tumours had a significantly better OS vs right sided tumours regardless of UPTR: UPTR HR 0.4 (0.2, 0.8); P = 0.006; no UPTR HR 0.2 (0.1, 0.4); P
Conclusions
In mCRC KRAS WT pts treated in 1st line with EGFRI + CT, UPTR seemed to improve outcomes particularly in right sided tumours. Table: 492P Median (95%CI) OS and PFSTable:
492P
| Right | Left | |||
|---|---|---|---|---|
| UPTR | No UPTR | UPTR | No UPTR | |
| Stage I-III at diagnosis, N | 9 | 31 | ||
| OS(m) | 34.9 | 28.9 | ||
| (30.6 -) | (17.6 -) | |||
| HR left vs right | 1.5 (0.6, 4.1) | |||
| p | 0.430 | |||
| PFS(m) | 14.3 | 10.8 | ||
| (8.5, 19.8) | (7.6, 13.9) | |||
| HR left vs right | 1.7 (0.7, 4.2) | |||
| p | 0.281 | |||
| Stage IV at diagnosis, N | 18 | 24 | 78 | 100 |
| OS(m) | 20.9 | 10.6 | 36.9 | 26.5 |
| (5.9, 34.2) | (6.3, 11.8) | (25.3, 45.8) | (20.7, 32.0) | |
| HR No UPTR vs UPTR | 2.1 (1.0, 4.3) | 1.4 (1.0, 2.0) | ||
| p | 0.038 | 0.088 | ||
| UPTR | ||||
| HR left vs right | 0.4 (0. 2, 0.8) | |||
| p | 0.006 | |||
| HR Stage IV vs Stage I-III | 4.4 (1.4, 13.9) | 1.0 (0.6, 1.8) | ||
| p | 0.019 | 0.931 | ||
| No-UPTR | ||||
| HR left vs right | 0.2 (0.1, 0.4) | |||
| p | Clinical trial identificationMACRO-2 trial: NCT01161316 - PLANET trial: NCT00885885 Legal entity responsible for the studySpanish Cooperative Group for the Treatment of Digestive Tumors (TTD) FundingAmgen S.A. (PLANET) and Merck. S. L. (MACRO-2) DisclosureM. Valladares-Ayerbes: Consultant or advisory relationship and honoraria: Roche, Amgen, Merck Serono. A. García-Tapiador: Consultant or advisory role and honoraria: Merck. E. Aranda Aguilar: Advisory role from Amgen, Bayer, Celgene, Merck, Roche, Sanofi. All other authors have declared no conflicts of interest. Resources from the same session2418 - Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer.Presenter: Ken Imaizumi Session: Poster display session Resources: Abstract 2581 - The ADC value of post-RT might predict TRG after neoadjuvant radiotherapy for local advanced rectal cancerPresenter: Wu Junxin Session: Poster display session Resources: Abstract 3513 - Polyethylene Glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancerPresenter: Giammaria Fiorentini Session: Poster display session Resources: Abstract 4702 - Neoadjuvant Systemic Chemotherapy prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the treatment of Peritoneal Carcinomatosis from Colorectal CancerPresenter: Nethanel Asher Session: Poster display session Resources: Abstract 3843 - Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): final results from an international trial (EORTC 05011)Presenter: Carlo Garufi Session: Poster display session Resources: Abstract 4961 - A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)Presenter: Antonio Avallone Session: Poster display session Resources: Abstract 5518 - First-in-Human Phase I Study of Bacterial RNA Interference Therapeutic CEQ508 in Patients with Familial Adenomatous Polyposis (FAP)Presenter: Vuong Trieu Session: Poster display session Resources: Abstract 3024 - A Multicentre Phase I/II Study of TAS-102 with Nintedanib in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (N-TASK FORCE: EPOC1410)Presenter: Kentaro Yamazaki Session: Poster display session Resources: Abstract 3654 - BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAF-V600E Metastatic Colorectal Cancer (mCRC)Presenter: Sanne Huijberts Session: Poster display session Resources: Abstract 3085 - Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: a retrospective, registry-based analysisPresenter: Tomas Buchler Session: Poster display session Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||